Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function

• 作者: Shao-long HE Yu-hang CHENG Di WANG Meng-lei XU Yi-mei QUE Yan-jie XU Liang-ming MA Chun-rui LI Jian-feng ZHOU
• 来源期刊: 当代医学科学（英文）
• 年，卷（期）: 2021,（3）
• 所属期刊栏目: HEMATOLOGY COLUMN
• 页码范围: 474-481
• 页数: 8页
• 语种: 英文
• DOI: 10.1007/s11596-021-2373-7

摘要

Anti-B cell maturation antigen(BCMA)chimeric antigen receptor(CAR)T-cell therapy is effective and well-tolerated for refractory or relapsed multiple myeloma(RRMM).The purpose of the present study was to analyze efficacy in RRMM patients with renal impairment treated by anti-BCMA CAR-T cell therapy.A total of 59 RRMM patients were selected,and divided into impaired renal function(IRF)group[baseline estimated glomerular filtration rate(eGFR)＜90 mL/min/1.73 m2(n=18)]and normal renal function(NRF)group(baseline eGFR≥90 mL/min/1.73 m2,n=41).For patients with IRF,eGFR at the 6th month post-CAR-T cells infusion was significantly higher than the baseline(P＜0.05).The multivariate analysis showed that light chain type and beta-2 micro-globulin(beta-2M)were associated factors with the decrease of serum creatinine.Median progression-free survival(PFS)in the NRF group and IRF group was 266 days and 181 days respectively.Overall survival(OS)in the NRF group and IRF group was 877 days and 238 days respectively.There was no significant difference in the objective response rate(ORR)between the IRF group and the NRF group.It is suggested that CAR-T cells therapy could improve the renal function during the treatment of RRMM.The renal function could be more significantly improved in RRMM patients with light chain type than with other types.